Tallac Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for TAC-001, a First-in-Class Toll-like Receptor 9 (TLR9) Agonist Antibody Conjugate for Patients with Advanced Solid Tumors
— TAC-001 will be the First Candidate from Tallac’s Novel Toll-like Receptor Agonist Antibody Conjugate (TRAAC) Platform to Enter Clinical Trials — TAC-001 Integrates B cells and TLR9 Activation to Trigger Innate and Adaptive Anti-tumor Immune Responses — Tallac Plans to Initiate a Phase 1/2 Clinical Study of Systemically Administered TAC-001 for Patients with Advanced … [Read more…]